Substituted tetrahydro1H-pyrazolo(3,4-c)pyridines, compositions containing same and use

Details for Australian Patent Application No. 2004256945 (hide)

Owner Aventis Pharma S.A.

Inventors Cherrier, Marie-Pierre; Thompson, Fabienne; Gauzy-Lazo, Laurence; Baudoin, Bernard; Tabart, Michel; Viviani, Fabrice; Clerc, Francois; Mailliet, Patrick; Souaille, Catherine; Halley, Frank; Damiano, Teresa; Bouchard, Herve

Agent Watermark

Pub. Number AU-B-2004256945

PCT Pub. Number WO2005/007653

Priority 03/08441 10.07.03 FR; 03/08442 10.07.03 FR

Filing date 8 July 2004

Wipo publication date 27 January 2005

Acceptance publication date 20 August 2009

International Classifications

A61K 31/437 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2005/007653 Priority application(s): WO2005/007653

20 August 2009 Application Accepted

  Published as AU-B-2004256945

17 December 2009 Standard Patent Sealed

3 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004256947-Hydroxyapatite calcium phosphate granules, method for preparing same and uses thereof

2004256892-Kappa agonists, especially for the treatment and/or prophylaxis of irritable bowel syndrome